In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

Obesity, myocardial function, geometry, and prognosis in acute heart failure

Session New insight in the evaluation of myocardial systolic and diastolic function

Speaker Chan Soon Park

Congress : EuroEcho-Imaging 2018

  • Topic : imaging
  • Sub-topic : Echocardiography: Systolic and Diastolic Function
  • Session type : Moderated Posters
  • FP Number : 554

Authors : C S Park (Seoul,KR), JJP Park (Seongnam,KR), JJP Park (Seongnam,KR), J-HP Park (Daejeon,KR), G-YC Cho (Seongnam,KR), YEY Yoon (Seongnam,KR), Y-JC Choi (Seoul,KR)


C S Park1 , JJP Park2 , JJP Park2 , J-HP Park3 , G-YC Cho2 , YEY Yoon2 , Y-JC Choi1 , 1Seoul National University Hospital, Cardiovascular Center - Seoul - Korea Republic of , 2Seoul National University Bundang Hospital, Cardiovascular center - Seongnam - Korea Republic of , 3Chungnam National University Hospital - Daejeon - Korea Republic of ,

European Heart Journal - Cardiovascular Imaging ( 2019 ) 20 ( Supplement 1 ), i331

Background/Introduction: Left ventricular-ejection fraction (LV-EF) may not accurately reflect LV systolic function in obese subjects, who frequently have altered LV geometry. 
Purpose: To explore whether myocardial function and structure, assessed by left ventricular (LV)-global longitudinal strain (GLS) and LV geometry, can explain the protective association of body mass index (BMI) with mortality in patients with acute heart failure (HF) and be used to improve risk prediction in this population.
Methods: We enrolled 2021 overweight-to-obese (BMI =23 kg/m2) and 1543 normal-weight patients with acute HF admitted from January 2009 to December 2016 with a median follow-up of 33.7 months. LV-GLS, LV-ejection fraction, LV geometry, and conventional echocardiographic measures were obtained. The primary outcome was all-cause mortality.
Results: Compared with normal-weight patients with HF, overweight-to-obese patients had a lower proportion of eccentric hypertrophy (62.4% vs. 49.1%, p<0.001), where the mean LV-GLS value and survival rate were lowest among LV geometric patterns. Higher BMIs were associated with lower mortality risks overall and in all subgroups according to LV-GLS or LV geometry, with a relatively steeper association among patients with high LV-GLS than in those with low LV-GLS. Overweight-to-obese patients with high LV-GLS had the lowest mortality risk (29.2%); normal-weight patients with high LV-GLS (40.6%), overweight-to-obese patients with low LV-GLS (39.0%), and normal-weight patients with low LV-GLS (50.6%) had progressively greater risks (p for trend <0.001). Patients with metabolically healthy obesity had better survival than those with metabolically unhealthy obesity (log-rank p<0.001), metabolically healthy normal-weight (log-rank p=0.001), and metabolically unhealthy normal-weight (log-rank p<0.001).
Conclusions: Overweight-to-obese patients with HF have distinct echocardiographic characteristics, such as less deterioration in myocardial function and LV geometry, compared with normal-weight patients, which may provide insights into the mechanisms underlying the protective effect of higher BMI in HF patients. . Metabolically healthy obese patients may have better survival than those with metabolically unhealthy obesity, suggesting potential therapeutic implications of targeting metabolic abnormalities in this population.

The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are